Patterns of allergic reactivity and disease in Olympic athletes.

OBJECTIVE: Because the Sydney Olympic Games were being held in the spring, we wished to examine the prevalence of allergic disorders in the Australian Olympic and Paralympic athletes and to examine patterns of allergic reactivity and medication use for the treatment of allergic symptoms. DESIGN: A survey case series of Australian Olympic and Paralympic athletes. SETTING: Screening was conducted on team processing days. PARTICIPANTS: Prospective members of the Australian Olympic and Paralympic teams. INTERVENTION: A questionnaire seeking information on the presence of allergic disorders, symptoms, family history, and medication use was administered. Skin-prick tests (SPT) for sensitivity to common aeroallergens was performed. OUTCOME MEASURES: Athletes were classified as atopic or non-atopic, and patterns of reactivity were examined according to sporting category. RESULTS: Of the athletes, 56% had a positive SPT to at least 1 allergen, with 34% reacting to at least 1 seasonal allergen. There was no significant association between skin test reactivity and sporting category. Of the athletes, 37% had allergic rhinoconjunctivitis (AR/C), whereas 24% had seasonal allergic rhinoconjunctivitis (SAR/C). Approximately one-third of all those with AR/C had a history of asthma, whereas approximately one-fifth had a history of atopic dermatitis. Swimmers were most likely to have asthma, AR/C, and positive skin tests to any allergen. Very few athletes with self-reported AR/C took any medication to relieve their symptoms. CONCLUSIONS: Allergic disorders are common among athletes from all sports. The known impact of AR/C on quality of life necessitates that it be screened for and managed appropriately.

Return to full normal activities including work at two weeks after acute myocardial infarction.

Patients are generally advised to return to full normal activities, including work, 6 to 8 weeks after acute myocardial infarction (AMI). We assessed the outcomes of early return to normal activities, including work at 2 weeks, after AMI in patients who were stratified to be at a low risk for future cardiac events. Patients were considered for randomization before discharge if they had no angina, had left ventricular ejection fraction >40%, a negative result from a symptom-limited exercise stress test for ischemia (<2 mm ST depression) at 1 week, and achieved >7 METs. Patients with left ventricular ejection fraction <40% were included only if they did not have inducible ventricular tachycardia at electrophysiologic studies. Seventy-two patients were randomized to return to normal activities at 2 weeks and 70 patients to undergo standard cardiac rehabilitation and return to normal activities at 6 weeks after AMI. There were no deaths or heart failure in either group. There was no significant difference in the incidence of reinfarction, revascularization, left ventricular function, lipids, body mass index, smoking, or exercise test results at 6 months. In conclusion, return to full normal activities, including work at 2 weeks, after AMI appears to be safe in patients who are stratified to a low-risk group. This should have significant medical and socioeconomic implications.

Allergic rhinoconjunctivitis in elite athletes: optimal management for quality of life and performance.

Allergic rhinoconjunctivitis is a common condition with a peak incidence in the age range of the majority of elite athletes. The condition has been shown to have a significant impact on the quality of life of those affected and poses particular challenges when present in the elite athlete. When an athlete is looking for exceptional performance at events such as the Olympic Games, any factor which affects quality of life by interfering with sleep, decreasing the ability to concentrate, or reducing peak physical fitness, may have a significant impact on the ability to perform at one's best. Optimal management begins with correct diagnosis and identification of triggering factors. There are a number of therapeutic options available to the treating physician. When formulating a management plan for the elite athlete, the physician must consider "doping" rules and the possible effect of medication on athletic performance. Medication choices include the newer, non-sedating antihistamines, used either orally or topically, and the prophylactic use of intranasal corticosteroids. When allergic conjunctivitis is the principal problem, the newer, topical antihistamines are highly effective and have a rapid onset of action. Since avoidance strategies are rarely practical for the athlete, consideration should be given to strategies such as immunotherapy, where long-term benefit is possible.

Effects of intranasal budesonide on symptoms, quality of life, and performance in elite athletes with allergic rhinoconjunctivitis.

OBJECTIVE: To assess change in symptoms, quality of life (QOL), and performance ability before, during, and after treatment with budesonide in a group of Olympic and Paralympic athletes with seasonal allergic rhinoconjunctivitis (SAR/C). DESIGN: Because budesonide has already been proven to be an effective and well-tolerated treatment of SAR/C(1), an open-label treatment format was used. SETTING: The study was community-based with participating athletes preparing for Olympic competition. PARTICIPANTS: Olympic and Paralympic athletes were screened for the presence of SAR/C using history and positive skin test results for pollen allergens. INTERVENTIONS: All were offered treatment with intranasal budesonide, applied to each nostril, once daily for eight weeks. OUTCOME MEASUREMENTS: Symptom and medication diaries were completed before treatment and after 4 and 8 weeks of treatment. Similarly, Quality of Life (QOL) was measured with the Rhinoconjunctivitis Quality of Life Questionnaire. As a secondary outcome measure, the ability to train and compete was assessed using a performance diary. RESULTS: Of the 236 athletes eligible for the study, 145 (61%) agreed to participate. Forty-six percent of the athletes who were dispensed treatment did not return questionnaires. For those returning questionnaires, scores between baseline (week 0) and weeks 4 and 8 were calculated for total symptoms, QOL, and performance scores. There were statistically significant improvements in symptoms, QOL, and performance scores in athletes who used intranasal budesonide. CONCLUSION: SAR/C is a common condition and has demonstrable negative effects on athletes. Better education of coaches and athletes is necessary to ensure that the condition is correctly diagnosed and treated, with safe, effective, permitted medication.